These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27003665)

  • 21. Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein.
    Cheng PH; Li CL; Her LS; Chang YF; Chan AW; Chen CM; Yang SH
    Brain Struct Funct; 2013 Jan; 218(1):283-94. PubMed ID: 22422149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorescence Imaging of Huntingtin mRNA Knockdown.
    Oh E; Liu Y; Sonar MV; Merry DE; Wickstrom E
    Bioconjug Chem; 2018 Apr; 29(4):1276-1282. PubMed ID: 29451775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
    Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
    PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease.
    Menalled L; Zanjani H; MacKenzie L; Koppel A; Carpenter E; Zeitlin S; Chesselet MF
    Exp Neurol; 2000 Apr; 162(2):328-42. PubMed ID: 10739639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range.
    Majumder P; Raychaudhuri S; Chattopadhyay B; Bhattacharyya NP
    Cell Mol Neurobiol; 2007 Dec; 27(8):1127-45. PubMed ID: 17902043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Fresh Look at Huntingtin mRNA Processing in Huntington's Disease.
    Romo L; Mohn ES; Aronin N
    J Huntingtons Dis; 2018; 7(2):101-108. PubMed ID: 29865084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.
    Tang B; Seredenina T; Coppola G; Kuhn A; Geschwind DH; Luthi-Carter R; Thomas EA
    Neurobiol Dis; 2011 Jun; 42(3):459-67. PubMed ID: 21334439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.
    Olson SD; Kambal A; Pollock K; Mitchell GM; Stewart H; Kalomoiris S; Cary W; Nacey C; Pepper K; Nolta JA
    Mol Cell Neurosci; 2012 Mar; 49(3):271-81. PubMed ID: 22198539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense oligonucleotide-mediated disruption of HTT caspase-6 cleavage site ameliorates the phenotype of YAC128 Huntington disease mice.
    Kuijper EC; Overzier M; Suidgeest E; Dzyubachyk O; Maguin C; Pérot JB; Flament J; Ariyurek Y; Mei H; Buijsen RAM; van der Weerd L; van Roon-Mom W
    Neurobiol Dis; 2024 Jan; 190():106368. PubMed ID: 38040383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Full sequence of mutant huntingtin 3'-untranslated region and modulation of its gene regulatory activity by endogenous microRNA.
    Kim KH; Abu Elneel K; Shin JW; Keum JW; Seong D; Kwak S; Lee R; Gusella JF; MacDonald ME; Seong IS; Lee JM
    J Hum Genet; 2019 Oct; 64(10):995-1004. PubMed ID: 31296921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway.
    Hu J; Liu J; Yu D; Chu Y; Corey DR
    Nucleic Acids Res; 2012 Dec; 40(22):11270-80. PubMed ID: 23042244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
    Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
    J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
    Dufour BD; Smith CA; Clark RL; Walker TR; McBride JL
    Mol Ther; 2014 Apr; 22(4):797-810. PubMed ID: 24390280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
    Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
    Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer: From Wild-Type to Mutant Huntingtin.
    Thion MS; Humbert S
    J Huntingtons Dis; 2018; 7(3):201-208. PubMed ID: 29889077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.
    Goold R; Flower M; Moss DH; Medway C; Wood-Kaczmar A; Andre R; Farshim P; Bates GP; Holmans P; Jones L; Tabrizi SJ
    Hum Mol Genet; 2019 Feb; 28(4):650-661. PubMed ID: 30358836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells.
    Murmann AE; Gao QQ; Putzbach WE; Patel M; Bartom ET; Law CY; Bridgeman B; Chen S; McMahon KM; Thaxton CS; Peter ME
    EMBO Rep; 2018 Mar; 19(3):. PubMed ID: 29440125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.